The CA-1 Cancer Screening - Women panel is specifically designed as an initial screening tool for the early detection of various cancers that commonly affect women. This panel combines several tumor markers and protein measurements, each carefully selected for their relevance in detecting specific cancer types. The panel is an important resource for those who are at increased risk of cancer, either due to family history, genetic predisposition, or other risk factors. By measuring specific biomarkers, this panel helps in identifying cancer at an early stage, where treatment can be more effective and less invasive.

The Cancer Screening - Women Panel is a comprehensive set of blood tests designed to detect various cancer markers in women. This panel assesses levels of specific proteins that can be elevated in the presence of certain types of cancer. By measuring these markers, healthcare providers can gain valuable insights into a patient's risk of having cancer, monitor the progression of the disease, and evaluate the effectiveness of treatment.

 The CA-2 Cancer Screening - Women panel is a specialized diagnostic tool designed for the early detection and ongoing monitoring of various cancers specifically in women. It expands upon basic cancer screening by including additional markers that provide a wider range of detection and insight into different types of cancers. This panel is particularly valuable for women who are at increased risk due to genetic predispositions, family history, or environmental factors. It helps in the early identification of cancer, potentially improving the effectiveness of treatments and increasing the chances of successful outcomes.

 The CA-3 Cancer Screening - Women panel is an extensive diagnostic tool designed for an in-depth analysis of various cancer-related markers, specifically tailored for women. This advanced screening panel integrates additional markers to enhance the detection and monitoring capabilities for a broad spectrum of cancers. It is instrumental in providing a comprehensive overview of a woman's cancer risk profile, facilitating early intervention, and guiding effective treatment strategies.

 The CA-4 Cancer Screening - Women panel is the most comprehensive diagnostic tool available for assessing cancer risk and monitoring the health of women potentially at high risk for various cancers. It encompasses an extensive range of biomarkers, each specifically chosen to detect early signs of cancer and monitor treatment progress or recurrence. This panel is essential for women with a significant family history of cancer, known genetic predispositions, or those who have had previous cancer diagnoses and need close surveillance.

 The Cancer Screening - Men panel is a comprehensive diagnostic tool designed to detect early signs of various cancers in men. This panel includes a series of tests that measure specific biomarkers associated with different types of cancer. By assessing these biomarkers, healthcare providers can identify the presence of cancer at an early stage, when treatment is often more effective. This panel is crucial for men who are at higher risk of developing cancer due to factors such as age, family history, or lifestyle.

The CA 15-3 Test measures cancer antigen 15-3 levels in blood, often used to monitor breast cancer treatment and progression. Elevated levels may suggest advanced breast cancer, metastasis, or recurrence, while non-cancer conditions can also affect results. Doctors order this test alongside imaging and other labs to track therapy response or detect changes in disease status. Results help guide ongoing management of breast cancer and patient care.

The CA 27.29 Test measures cancer antigen 27.29 levels in blood to help monitor breast cancer treatment, progression, or recurrence. Elevated levels may indicate advanced or metastatic breast cancer, though non-cancer conditions can also affect results. Doctors order this test alongside imaging or other tumor markers to track therapy response. Results provide valuable insight for ongoing breast cancer management and long-term patient care.